Checkmate Pharmaceuticals, Inc.
CMPIDelisted May 31, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001651431
Checkmate Pharmaceuticals, Inc. was delisted on May 31, 2022; its insiders filed their last Form 4 on May 31, 2022; 26 institutions reported holding it in 13F filings for Q1 2022, worth $54.8M in total; no superinvestor held it.
Q1 2022 vs. Q4 2021
How the institutions holding Checkmate Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 25 | 26 | +1 |
| Shares | 16.1M | 17.2M | +1.04M (+6.5%) |
| Value | $46.3M | $54.8M | +$8.48M (+18.3%) |
New holders (4)
Institutions that held Checkmate Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 1,333,254 | $4.25M | 1.30% |
| Barclays PLC | 14,553 | $46.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,940 | $6.00K | 0.00% |
| JPMorgan Chase & Co | 49 | $0 | 0.00% |
Sold out (3)
Institutions that held Checkmate Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Ensign Peak Advisors, Inc | 93,334 | $268.0K |
| Millennium Management LLC | 10,633 | $31.0K |
| Royal Bank of Canada | 168 | $0 |